Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein.

@article{Mizoi2014DistinctionBM,
  title={Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein.},
  author={Mutsumi Mizoi and Madoka Yoshida and Ryotaro Saiki and Masaaki Waragai and Kenichi Uemura and Hiroyasu Akatsu and Keiko Kashiwagi and Kazuei Igarashi},
  journal={Clinica chimica acta; international journal of clinical chemistry},
  year={2014},
  volume={430},
  pages={150-5}
}
BACKGROUND We found previously that the amyloid β40/42 (Aβ40/42) ratio and the level of protein-conjugated acrolein (PC-Acro) in plasma were increased in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects. We determined whether MCI and AD subjects can be differentiated based on the levels of Aβ40, Aβ42, and PC-Acro in cerebrospinal fluid (CSF). METHODS Aβ40, Aβ42, PC-Acro, Tau and phosphorylated Tau in CSF were measured by ELISA. RESULTS Median values of Aβ40, Aβ40/PC… CONTINUE READING
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…